تقرير
أعرض في EDS

Elevated serum levels of T-cell immunoglobulin and mucin-domain containing molecule 3 in patients with systemic inflammation following COVID-19 vaccination.

التفاصيل البيبلوغرافية
العنوان: Elevated serum levels of T-cell immunoglobulin and mucin-domain containing molecule 3 in patients with systemic inflammation following COVID-19 vaccination.
المؤلفون: Hsieh MC; Division of Allergy-Immunology-Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC., Yu WC; Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.; Faculty of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC., Weng CC; Faculty of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.; Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC., Chen WJ; Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.; Shu-Tien Urological Institute, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC., Chen CK; Division of Cardiopulmonary Radiology, Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.; Department of Radiology, Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC., Lee YC; Division of Cardiopulmonary Radiology, Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC., Chen MH; Division of Allergy-Immunology-Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.; Faculty of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
المصدر: Journal of the Chinese Medical Association : JCMA [J Chin Med Assoc] 2023 Sep 01; Vol. 86 (9), pp. 818-825. Date of Electronic Publication: 2023 Jul 23.
نوع المنشور: Case Reports
اللغة: English
بيانات الدورية: Publisher: Wolters Kluwer Health Country of Publication: Netherlands NLM ID: 101174817 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1728-7731 (Electronic) Linking ISSN: 17264901 NLM ISO Abbreviation: J Chin Med Assoc Subsets: MEDLINE
أسماء مطبوعة: Publication: 2019- : [Alphen aan den Rijn, The Netherlands] : Wolters Kluwer Health
Original Publication: Taipei, Taiwan : Chinese Medical Association, c2003-
مواضيع طبية MeSH: COVID-19* , COVID-19 Vaccines*/adverse effects, Humans ; Male ; Becaplermin ; ChAdOx1 nCoV-19 ; Inflammation/chemically induced ; Mucin-3 ; Mucins ; T-Lymphocytes ; Vaccination ; Adult
مستخلص: Background: ChAdOx1 nCoV-19 vaccine has been widely used. Some unexpected adverse effects such as the development of systemic hyper inflammation with multiorgan involvement after vaccination, in rare cases, have been reported. However, its pathogenesis remains unclear.
Methods: This study recruited two cases who suffered from systemic inflammation following ChAdOx1 nCoV-19 vaccine and two 30-year-old male volunteers without underlying disease who have received ChAdOx1 nCoV-19 vaccine as control group. Blood samples were collected from our patients and healthy subjects before and after treatment with anti-inflammatory agent such as glucocorticoid and tocilizumab. The immune profile from our patients and healthy controls were measured using a human XL cytokine Proteome Profiler array (ARY022b, R&D Systems).
Results: Biochemical parameters revealed leukocytosis with segmented neutrophil dominance and elevated serum levels of C-reactive protein (CRP), erythrocyte sedimentation rate, and ferritin in these two patients. The cytokine array revealed that mean levels of T cell immunoglobulin and mucin-domain containing-3 (TIM-3) (3640.3 vs 1580.5 pixels per inch [ppi]), B-cell activating factor (BAFF) (3036.8 vs 1471.0 ppi), urokinase plasminogen activator surface receptor (uPAR) (1043.1 vs 516.8 ppi), Resistin (1783.7 vs 711.3 ppi), platelet-derived growth factor (PDGF)-AB/BB (1980.7 vs 939.7 ppi), macrophage inflammatory protein-3-beta (MIP-3β) (911.9 vs 346.2 ppi), and interferon-inducible T-cell alpha chemoattractant (I-TAC) (1026.3 vs 419.7 ppi) were 2-fold higher in the patients than in normal subjects who received ChAdOx1 nCoV-19 vaccine.
Conclusion: We demonstrated that systemic inflammation may occur in subjects who have received the ChAdOx1 nCoV-19 vaccination. Moreover, we proposed immune markers, which may be implicated in the pathogenesis of systemic inflammation following COVID-19 vaccination as potential diagnostic biomarkers.
Competing Interests: Conflicts of interest: The authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article.
(Copyright © 2023, the Chinese Medical Association.)
References: Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al.; COVID-19 Genomics UK (COG-UK) Consortium. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19:409–24.
Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, et al. A global database of COVID-19 vaccinations. Nat Hum Behav. 2021;5:947–53.
Pavord S, Scully M, Hunt BJ, Lester W, Bagot C, Craven B, et al. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med. 2021;385:1680–9.
Park JW, Yu SN, Chang SH, Ahn YH, Jeon MH. Multisystem inflammatory syndrome in an adult after COVID-19 vaccination: a case report and literature review. J Korean Med Sci. 2021;36:e312.
Choi YK, Moon JY, Kim J, Yoo IS, Kwon GY, Bae H, et al. Postvaccination multisystem inflammatory syndrome in adult with no evidence of prior SARS-CoV-2 infection. Emerg Infect Dis. 2022;28:411–4.
Aksu K, Keser G, Gunaydin G, Ozbek SS, Colakoglu Z, Gumusdis G, et al. Erectile dysfunction in Behcet’s disease without neurological involvement: two case reports. Rheumatology (Oxford). 2000;39:1429–31.
Patel P, DeCuir J, Abrams J, Campbell AP, Godfred-Cato S, Belay ED. Clinical characteristics of multisystem inflammatory syndrome in adults: a systematic review. JAMA Netw Open. 2021;4:e2126456.
Weatherhead JE, Clark E, Vogel TP, Atmar RL, Kulkarni PA. Inflammatory syndromes associated with SARS-CoV-2 infection: dysregulation of the immune response across the age spectrum. J Clin Invest. 2020;130:6194–7.
Bartsch YC, Wang C, Zohar T, Fischinger S, Atyeo C, Burke JS, et al. Humoral signatures of protective and pathological SARS-CoV-2 infection in children. Nat Med. 2021;27:454–62.
Vella LA, Giles JR, Baxter AE, Oldridge DA, Diorio C, Kuri-Cervantes L, et al.; UPenn COVID Processing Unit. Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19. Sci Immunol. 2021;6:eabf7570.
Cheng MH, Zhang S, Porritt RA, Noval Rivas M, Paschold L, Willscher E, et al. Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation. Proc Natl Acad Sci U S A. 2020;117:25254–62.
Angeli F, Spanevello A, Reboldi G, Visca D, Verdecchia P. SARS-CoV-2 vaccines: lights and shadows. Eur J Intern Med. 2021;88:1–8.
Karampelas M, Dalamaga M, Karampela I. Does COVID-19 involve the retina? Ophthalmol Ther. 2020;9:693–5.
Sheth JU, Narayanan R, Goyal J, Goyal V. Retinal vein occlusion in COVID-19: a novel entity. Indian J Ophthalmol. 2020;68:2291–3.
Invernizzi A, Schiuma M, Parrulli S, Torre A, Zicarelli F, Colombo V, et al. Retinal vessels modifications in acute and post-COVID-19. Sci Rep. 2021;11:19373.
Lei Y, Zhang J, Schiavon CR, He M, Chen L, Shen H, et al. SARS-CoV-2 spike protein impairs endothelial function via downregulation of ACE 2. Circ Res. 2021;128:1323–6.
Das M, Zhu C, Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev. 2017;276:97–111.
Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol. 2020;20:173–85.
Banerjee H, Kane LP. Immune regulation by Tim-3. F1000Res. 2018;7:316.
Ueland T, Heggelund L, Lind A, Holten AR, Tonby K, Michelsen AE, et al. Elevated plasma sTIM-3 levels in patients with severe COVID-19. J Allergy Clin Immunol. 2021;147:92–8.
Modabber Z, Shahbazi M, Akbari R, Bagherzadeh M, Firouzjahi A, Mohammadnia-Afrouzi M. TIM-3 as a potential exhaustion marker in CD4(+) T cells of COVID-19 patients. Immun Inflamm Dis. 2021;9:1707–15.
Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol. 2002;2:465–75.
Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol. 2014;10:365–73.
Uzzan M, Colombel JF, Cerutti A, Treton X, Mehandru S. B cell-activating factor (BAFF)-targeted B cell therapies in inflammatory bowel diseases. Dig Dis Sci. 2016;61:3407–24.
Andreou NP, Legaki E, Dovrolis N, Boyanov N, Georgiou K, Gkouskou K, et al. B-cell activating factor (BAFF) expression is associated with Crohn’s disease and can serve as a potential prognostic indicator of disease response to Infliximab treatment. Dig Liver Dis. 2021;53:574–80.
Genua M, D’Alessio S, Cibella J, Gandelli A, Sala E, Correale C, et al. The urokinase plasminogen activator receptor (uPAR) controls macrophage phagocytosis in intestinal inflammation. Gut. 2015;64:589–600.
D’Alonzo D, De Fenza M, Pavone V. COVID-19 and pneumonia: a role for the uPA/uPAR system. Drug Discov Today. 2020;25:1528–34.
Tripathi D, Kant S, Pandey S, Ehtesham NZ. Resistin in metabolism, inflammation, and disease. FEBS J. 2020;287:3141–9.
Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation. 2005;111:932–9.
Filkova M, Haluzik M, Gay S, Senolt L. The role of resistin as a regulator of inflammation: implications for various human pathologies. Clin Immunol. 2009;133:157–70.
Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 1999;18:6853–66.
Akahoshi T, Sasahara T, Namai R, Matsui T, Watabe H, Kitasato H, et al. Production of macrophage inflammatory protein 3alpha (MIP-3alpha) (CCL20) and MIP-3beta (CCL19) by human peripheral blood neutrophils in response to microbial pathogens. Infect Immun. 2003;71:524–6.
Liu Z, Chen X, Wang X, Chen X, Song CH, Du Y, et al. Chemokine CXCL11 links microbial stimuli to intestinal inflammation. Clin Exp Immunol. 2011;164:396–406.
Callahan V, Hawks S, Crawford MA, Lehman CW, Morrison HA, Ivester HM, et al. The pro-inflammatory chemokines CXCL9, CXCL10 and CXCL11 are upregulated following SARS-CoV-2 infection in an AKT-dependent manner. Viruses. 2021;13:1062.
Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19:12–9.
De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al.; PRINTO. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385–95.
Menzella F, Fontana M, Salvarani C, Massari M, Ruggiero P, Scelfo C, et al. Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation. Crit Care. 2020;24:589.
Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis. 2021;73:e445–54.
Edinoff AN, Alpaugh ES, Newgaard O, Wajid I, Klapper RJ, Cornett EM, et al. Tocilizumab for severe COVID-19 infection and multisystem inflammatory syndrome in adults and children. Life (Basel). 2023;13:889.
Wang Q, Liu G, Teng Y, Feng X, Chen Z, Wang F, et al. Diagnostic value of peripheral TiM-3, NT proBNP, and Sestrin2 testing in left-to-right shunt congenital heart disease with heart failure. BMC Pediatr. 2023;23:7.
Kalra K, Eberhard J, Farbehi N, Chong JJ, Xaymardan M. Role of PDGF-A/B ligands in cardiac repair after myocardial infarction. Front Cell Dev Biol. 2021;9:669188.
Wang Z, Wang Y, Cui Y, Chen Z, Yi L, Zhu Z, et al. Association of serum BAFF levels with cardiovascular events in ST-segment elevation myocardial infarction. J Clin Med. 2023;12:1692.
Kruger R, Schutte R, Huisman HW, Hindersson P, Olsen MH, Eugen-Olsen J, et al. NT-proBNP, C-reactive protein and soluble uPAR in a bi-ethnic male population: the SAfrEIC study. PLoS One. 2013;8:e58506.
Cai X, Allison MA, Ambale-Venkatesh B, Jorgensen NW, Lima JAC, Muse ED, et al. Resistin and risks of incident heart failure subtypes and cardiac fibrosis: the multi-ethnic study of atherosclerosis. ESC Heart Fail. 2022;9:3452–60.
Teijaro JR, Farber DL. COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol. 2021;21:195–7.
المشرفين على المادة: 1B56C968OA (Becaplermin)
B5S3K2V0G8 (ChAdOx1 nCoV-19)
0 (COVID-19 Vaccines)
0 (Mucin-3)
0 (Mucins)
تواريخ الأحداث: Date Created: 20230723 Date Completed: 20230911 Latest Revision: 20230911
رمز التحديث: 20230911
DOI: 10.1097/JCMA.0000000000000969
PMID: 37481764
قاعدة البيانات: MEDLINE
الوصف
تدمد:1728-7731
DOI:10.1097/JCMA.0000000000000969